Predictions for Breast Cancer Cases by 2030

By the year 2030, it is estimated that there will be around 23.6 million new cases of breast cancer diagnosed globally each year. Early detection plays a crucial role in improving treatment success rates through various breast cancer drugs.

Understanding Hormone Receptor Status

Research indicates that patients who are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) typically present with a common form of early-detected breast cancer that is more manageable with treatment. Conversely, individuals diagnosed at later stages have fewer treatment options and consequently lower success rates.

The Impact of CDK4/6 Inhibitors

The landscape of breast cancer treatment evolved with the introduction of CDK4/6 inhibitors, which target essential proteins involved in the cell division cycle. This approach disrupts the dysfunctional cellular division that fuels tumor growth. Due to their efficacy in impeding tumor progression, these inhibitors received expedited approval from the U.S. Food and Drug Administration (FDA).

Approved CDK4/6 Inhibitors

Three CDK4/6 inhibitors have been approved for use primarily in advanced HR+ and HER2- breast cancer cases. Despite their similar biological targets, these drugs can be utilized interchangeably, leading to significant improvements in tumor growth reduction, lower toxicity, and extended survival rates.

Resistance and Efficacy of Different Drugs

However, pablociclib and ribociclib encountered challenges as some cancer cells developed resistance to their effects. In contrast, abemaciclib consistently demonstrated high rates of cancer cell death. To investigate further, researchers at Harvard Medical School conducted studies comparing the cellular growth rates, viability, and gene expression of these drugs in cell lines and animal models.

Comparative Advantages of Abemaciclib

The findings revealed that while all three drugs target the same protein inhibitors, abemaciclib showed a distinct advantage over pablociclib and ribociclib. It also influenced the activity of additional proteins linked to cancer progression. For instance, in tests involving artificially resistant cell lines, ribociclib had no impact, whereas abemaciclib effectively inhibited cancer cell growth.

Broader Implications for Cancer Treatment

The implications of these results extend beyond breast cancer treatment options. They highlight the importance of understanding the specific biological effects of marketed drugs, as variations in disease profiles among patients may explain differing drug efficacy.

Pre-Clinical Findings and Clinical Considerations

It is essential to note that the authors cautioned that these results stem from pre-clinical laboratory experiments and should be interpreted with caution when making clinical decisions regarding breast cancer drugs. Nonetheless, the study serves as a reminder that drugs marketed for the same target may not always deliver equal effectiveness across various scenarios.

Written by Stephanie Tsang

References

Breast Cancer Worldwide. (2019). Retrieved from https://www.abcglobalalliance.org/articles/breast-cancer-worldwide/

Hafner, M., Mills, C. E., Subramanian, K., Chen, C., Chung, M., Boswell, S. A., … Sorger, P. K. (2019). Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell Chemical Biology, 26(8). doi: 10.1016/j.chembiol.2019.05.005